New pill shows promise in shrinking rectal tumors before surgery
NCT ID NCT06850090
First seen May 04, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This phase 3 trial tests whether a newer oral chemotherapy drug, TAS-102, works better than the standard drug capecitabine when given with radiation before surgery for locally advanced rectal cancer. About 210 adults aged 18-75 with stage II or III rectal cancer will take part. The goal is to see if TAS-102 leads to more tumors completely disappearing (complete response) before or after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.